Faculty profile

Jacques Turgeon

Back to faculty

Professor EmeritusUniversité de Montréal

Jacques Turgeon

Professor Emeritus

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Emeritus professors are retired and rarely take new students.
4 publications in the last five years, latest in 2023.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2011.
Supervisor on 2 trainee awards (2 CIHR), most recently in 2010.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,249

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Google Scholar ResearchGate iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Latest papers

Multidrug Interactions: Why Do They Occur and How to Handle?
Clinical therapeutics · 2023 · senior author
Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report.
Journal of personalized medicine · 2022
Assessing the Impact of an Advanced Clinical Decision Support System on Medication Safety and Hospital Readmissions in an Innovative Transitional Care Model: A Pilot Study.
Journal of clinical medicine · 2022 · senior author

All 50 publications

Latest funding

DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)
CIHR · 2014 · Co-investigator
$750,000
THE MONTREAL CARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOcMET)
CFI · 2012 · Co-investigator
$2,312,056
The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs.
CIHR · 2011 · Nominated PI
$807,020

All 11 grants and awards

50 publications.

Multidrug Interactions: Why Do They Occur and How to Handle?

Dow P, Michaud V, Turgeon J

Clinical therapeutics20237 citationsSenior author

DOI: 10.1016/j.clinthera.2022.12.012 PMID: 36682993

Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report.

Muhn S, Amin NS, Bardolia C, Del Toro-Pagán N, Pizzolato K, Thacker D, Turgeon J, Tomaino C, Michaud V

Journal of personalized medicine20229 citationsOpen Access

DOI: 10.3390/jpm12060974 PMID: 35743759

Assessing the Impact of an Advanced Clinical Decision Support System on Medication Safety and Hospital Readmissions in an Innovative Transitional Care Model: A Pilot Study.

Bingham JM, Baugham L, Hilaneh A, Tranchina K, Arku D, Eckert B, Scovis N, Turgeon J

Journal of clinical medicine2022Senior author

DOI: 10.3390/jcm11082070 PMID: 35456163

Letter to the Editor: Geriatric emergency department revisits after discharge with Potentially Inappropriate Medications: A retrospective cohort study.

Turgeon J, Munger MA, Pace WD

The American journal of emergency medicine2022First author

DOI: 10.1016/j.ajem.2021.12.040 PMID: 34972584

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.

Al Rihani SB, Deodhar M, Darakjian LI, Dow P, Smith MK, Bikmetov R, Turgeon J, Michaud V

Drugs & aging202161 citationsOpen Access

DOI: 10.1007/s40266-021-00895-x PMID: 34751922

Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.

Michaud V, Dow P, Al Rihani SB, Deodhar M, Arwood M, Cicali B, Turgeon J

Clinical and translational science202153 citationsSenior authorOpen Access

DOI: 10.1111/cts.12882 PMID: 32888379

Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Darakjian L, Deodhar M, Turgeon J, Michaud V

International journal of molecular sciences202153 citationsOpen Access

DOI: 10.3390/ijms22094967 PMID: 34067027

Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier Level.

Al Rihani SB, Darakjian LI, Deodhar M, Dow P, Turgeon J, Michaud V

International journal of molecular sciences202153 citationsOpen Access

DOI: 10.3390/ijms22073742 PMID: 33916769

Determination of CYP450 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics.

Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V

International journal of molecular sciences202133 citationsOpen Access

DOI: 10.3390/ijms222312791 PMID: 34884595

Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.

Smith MK, Bikmetov R, Al Rihani SB, Deodhar M, Hafermann M, Dow P, Turgeon J, Michaud V

Clinical and translational science20218 citationsOpen Access

DOI: 10.1111/cts.13025 PMID: 33786990

DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)

Co-investigatorCIHR2014Team Grant: DSEN Collab Ctre Prospective Studies -Pharmacogenomics of Adverse...

Principal investigators: Kim, Richard B; Carleton, Bruce C; Ross, Colin J; Tirona, Rommel G

Keywords: Adverse Drug Reactions; Drug Metabolism; Pharmacogenomics; Pharmacokinetics; Pharmacology

$750,000

THE MONTREAL CARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOcMET)

Co-investigatorCFI2012Innovation Fund: Leading Edge Fund (2012 competition)

Principal investigators: Prentki, Marc

Keywords: Diabetes, obesity, metabolic syndrome, dyslipidemia, metabolomics, interactomics, bioinformatics, biomarkers, drug discovery LCMSMS, HPLC, PCR, rodent and human phenotyping, servers

$2,312,056

The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs.

Nominated PICIHR2011Operating Grant

Principal investigators: Turgeon, Jacques

Keywords: Cardiac Electrophysiology; Cytochromes P450; Drug Metabolism; Heart; Human; Potassium Channels; Qt-Prolonging Drugs

$807,020

Characterizing the Roles of Cytochrome P450 Isozymes in Breast Cancer

SupervisorCIHR2010Master's Award: Canada Graduate Scholarships

Principal investigators: Armstrong, Catherine L

Keywords: Anti-Cancer Drugs; Breast Cancer; Cancer; Cytochrome P450; Drug Metabolism; Inter-Subject Variability; Pharmacogenetics; Pharmacokinetics; Resistance; Stem Cells

$17,500

Pharmacogenetic study of warfarin

Co-investigatorCIHR2009Operating Grant

Principal investigators: Dubé, Marie-Pierre; Perreault, Sylvie

Keywords: Bleeding; Genetic Tests; Inr Fluctuations; Pharmacogenomics; Warfarin

$1,051,841

Études d'interactions médicamenteuses chez le volontaire sain suivant l'administration concomitante d'un substrat des CYP3As, le triazolam, et d'un substrat des Pgp, la fexofénadine, avant et pendant la co-administration d'un inhibiteur des CYP3As, la clarithromycine : étude clinique étudiant l'inhibition compétitive (dose unique) versus l'inhibition par formation de complexe métabolique des CYP3As (doses multiples).

SupervisorCIHR2009Master's Award: Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Huguet, Jade

Keywords: Complexe Métabolique; Cyp450; Glycoprotéine P; Inhibition Compétitive; Interactions Médicamenteuses; Polymorphismes Génétiques

$17,500

Predictors of Depression Treatment Response Following an Acute Coronary Syndrome

Co-investigatorCIHR2009Operating Grant: Prevention of Cardiovascular and Respiratory Diseases

Principal investigators: Frasure-Smith, Nancy E

Keywords: Antidepressant; Autonomic Nervous System; Coronary Heart Disease; Depression; Inflammatory Markers; Treatment Resistance

$559,006

Characterization of novel pathogenic roles of CYP450s in breast cancer

Nominated PICIHR2009Operating Grant - PA: Institute of Genetics (Bridge Funding)

Principal investigators: Turgeon, Jacques; Balicki, Danuta M

Keywords: Breast Cancer; Chemoresistance; Cytochrome P450; Drug Metabolism; Extrahepatic; Pharmacogenetics

$100,000

Programme de mobilisation de la propriété intellectuelle Compétition 2006 - REVALTECH -Le réseau québecois en valorisation des technologies issues de la recherche universitaire, collégiale et publique

Co-investigatorNSERC2006Intellectual Property Mobilization - Infrastructure

Principal investigators: Bourget, Edwin

$75,000

Centre de Pharmacogénomique de l'Université de Montréal

Co-investigatorCFI2006Innovation Fund: New Initiatives Fund 2006

Principal investigators: Tardif, Jean-Claude

Keywords: Pharmacogénomique, réponses médicamenteuses, toxicité, biomarqueurs, cardiovasculaire, ontogénomique, neurosciences, inflammation, oncologie, facteurs de risque

$5,515,557

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Jacques Turgeon

Research

Latest papers

Latest funding

Multidrug Interactions: Why Do They Occur and How to Handle?

Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report.

Assessing the Impact of an Advanced Clinical Decision Support System on Medication Safety and Hospital Readmissions in an Innovative Transitional Care Model: A Pilot Study.

Letter to the Editor: Geriatric emergency department revisits after discharge with Potentially Inappropriate Medications: A retrospective cohort study.

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.

Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.

Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier Level.

Determination of CYP450 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics.

Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.

DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)

THE MONTREAL CARDIOMETABOLIC BIOMARKER AND DRUG DISCOVERY CONSORTIUM (BIOcMET)

The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs.

Characterizing the Roles of Cytochrome P450 Isozymes in Breast Cancer

Pharmacogenetic study of warfarin

Predictors of Depression Treatment Response Following an Acute Coronary Syndrome

Characterization of novel pathogenic roles of CYP450s in breast cancer

Programme de mobilisation de la propriété intellectuelle Compétition 2006 - REVALTECH -Le réseau québecois en valorisation des technologies issues de la recherche universitaire, collégiale et publique

Centre de Pharmacogénomique de l'Université de Montréal

Frequent collaborators

Véronique Michaud

Simon de Denus

Marie-Pierre Dubé

Michel White

Anique Ducharme

Jean-Claude Tardif

Thao Huynh

Jean-Louis Chiasson

Isabelle Plante

Jean-Philippe Lambert

Maude St-Onge

Chantal Pharand

Marie Lordkipanidzé

Nadia Giannetti

Fahima Nekka

Lambert Busque

Eileen O'Meara

Benoît Panzini

Mario Talajic

Lyne Lalonde